Drug Patents owned by Sarepta Theraps Inc
1. List of Amondys 45 drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE48960 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(2 years from now) | |
| US9447415 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(2 years from now) | |
| US9228187 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(7 years from now) | |
| US10287586 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9758783 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(7 years from now) | |
| US10781450 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Feb 25, 2028 |
| New Chemical Entity Exclusivity (NCE) | Feb 25, 2026 |
Drugs and Companies using CASIMERSEN ingredient
NCE-1 date: 2025-02-25
Market Authorisation Date: 25 February, 2021
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping; Treatment of duchenne muscular dystrophy (dmd) in patients who have...
Dosage: SOLUTION;INTRAVENOUS
AMONDYS 45 family patents
60
United States
11
European Union
8
Australia
6
Korea, Republic of
5
Japan
5
Israel
4
Spain
4
New Zealand
3
Denmark
3
Poland
3
Croatia
3
Cyprus
3
Slovenia
2
Hong Kong
2
China
2
Portugal
2
Hungary
1
Austria
1
Turkey
1
RS
1
Germany
1
Brazil
1
Canada
1
Lithuania
2. List of Exondys 51 drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9018368 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(2 years from now) | |
| US10781451 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(2 years from now) | |
| US9243245 | SAREPTA THERAPS INC | Means and methods for counteracting muscle disorders |
Oct, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE47751 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(2 years from now) | |
| USRE48468 | SAREPTA THERAPS INC | Means and methods for counteracting muscle disorders |
Oct, 2028
(5 years from now) | |
| USRE47769 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Feb, 2029
(5 years from now) | |
| US10337003 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(10 years from now) | |
| US10364431 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(10 years from now) | |
| US9506058 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 19, 2023 |
Drugs and Companies using ETEPLIRSEN ingredient
Market Authorisation Date: 19 September, 2016
Treatment: Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Treatment of duchenne muscular dystrophy (dmd) in patients having a mutatio...
Dosage: SOLUTION;INTRAVENOUS
EXONDYS 51 family patents
86
United States
19
European Union
10
Japan
10
Israel
9
Spain
8
Australia
7
China
6
Hong Kong
5
Denmark
5
Canada
5
New Zealand
5
Cyprus
4
Poland
4
Croatia
4
Portugal
4
Netherlands
3
Slovenia
3
Hungary
2
Korea, Republic of
2
Mexico
1
Austria
1
Germany
1
Brazil
1
EA
3. List of Vyondys 53 drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10968450 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(2 years from now) | |
| US9024007 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(2 years from now) | |
| US9994851 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(2 years from now) | |
| US10227590 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(2 years from now) | |
| US10421966 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE47691 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(2 years from now) | |
| US10995337 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(2 years from now) | |
| US10266827 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(2 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 12, 2026 |
| New Chemical Entity Exclusivity (NCE) | Dec 12, 2024 |
Drugs and Companies using GOLODIRSEN ingredient
NCE-1 date: 2023-12-13
Market Authorisation Date: 12 December, 2019
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients having a confirmed mutation of the dmd gene that is amenable to exon 53 skipping
Dosage: SOLUTION;INTRAVENOUS
VYONDYS 53 family patents
53
United States
9
European Union
3
Spain
2
Croatia
2
Poland
2
Hong Kong
2
Cyprus
2
Slovenia
2
Australia
2
Denmark
1
Germany
1
Austria
1
Portugal
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic